Dietary marine fatty acids (fish oil) for asthma in adults and children

Francis CK Thien; Stefano De Luca; Rosalie K Woods; Michael J Abramson

doi:10.1002/14651858.CD001283

Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados
Guías
Temas

Revisiones y protocolos relacionados

Topics

Temas

Analysis 1.1

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 1 PEF ‐ end.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 2 PEF ‐ baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 3 PEF ‐ change.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.4

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 4 FEV1.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.5

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 5 Asthma symptom scores.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.6

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 6 Asthma medication usage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.7

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 7 Bronchial hyperresponsiveness (logged).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.1

Comparison 2 n‐3 supplementation versus placebo (cross‐over studies), Outcome 1 PEF ‐ end.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.3

Comparison 2 n‐3 supplementation versus placebo (cross‐over studies), Outcome 3 Asthma symptom scores.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.4

Comparison 2 n‐3 supplementation versus placebo (cross‐over studies), Outcome 4 Symptomatic deterioration.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 3.1

Comparison 3 adults versus children ‐ bronchial hyperresponsiveness (logged), Outcome 1 Adults versus Children.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.1

Comparison 4 adults versus children ‐ Asthma symptom scores, Outcome 1 Adults versus children.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1. n‐3 fatty acid supplementation versus placebo (parallel studies)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 PEF ‐ end Show forest plot	4	101	Std. Mean Difference (IV, Random, 95% CI)	1.05 [0.02, 2.08]

2 PEF ‐ baseline Show forest plot	4	101	Std. Mean Difference (IV, Random, 95% CI)	0.04 [‐0.48, 0.56]

3 PEF ‐ change Show forest plot	4	101	Std. Mean Difference (IV, Random, 95% CI)	0.51 [‐0.46, 1.47]

4 FEV1 Show forest plot	2	51	Mean Difference (IV, Fixed, 95% CI)	2.08 [‐4.77, 8.93]

5 Asthma symptom scores Show forest plot	5	124	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.09 [‐0.45, 0.27]

6 Asthma medication usage Show forest plot	4	101	Std. Mean Difference (IV, Random, 95% CI)	‐0.84 [‐2.11, 0.44]

7 Bronchial hyperresponsiveness (logged) Show forest plot	5	108	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.14 [‐0.52, 0.24]

Comparison 1. n‐3 fatty acid supplementation versus placebo (parallel studies)

Ir a la tabla de la revisión

Comparison 2. n‐3 supplementation versus placebo (cross‐over studies)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 PEF ‐ end Show forest plot	2	88	Mean Difference (IV, Fixed, 95% CI)	5.05 [‐34.29, 44.38]

3 Asthma symptom scores Show forest plot	1	30	Mean Difference (IV, Fixed, 95% CI)	‐0.03 [‐1.75, 1.69]

4 Symptomatic deterioration Show forest plot	1	56	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.28 [0.09, 0.84]

Comparison 2. n‐3 supplementation versus placebo (cross‐over studies)

Ir a la tabla de la revisión

Comparison 3. adults versus children ‐ bronchial hyperresponsiveness (logged)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Adults versus Children Show forest plot	5	108	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.14 [‐0.52, 0.25]

1.1 Adults	3	46	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.01 [‐0.61, 0.59]
1.2 Children	2	62	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.22 [‐0.72, 0.28]

Comparison 3. adults versus children ‐ bronchial hyperresponsiveness (logged)

Ir a la tabla de la revisión

Comparison 4. adults versus children ‐ Asthma symptom scores

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Adults versus children Show forest plot	5	130	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.06 [‐0.41, 0.29]

1.1 adults	3	62	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.25 [‐0.76, 0.27]
1.2 Children	2	68	Std. Mean Difference (IV, Fixed, 95% CI)	0.10 [‐0.38, 0.58]

Comparison 4. adults versus children ‐ Asthma symptom scores

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet